Chan Sylvie Sw, Vainauskas Osvaldas, Attard Gerhardt
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI195102.
Tumor heterogeneity in metastatic prostate cancer (mPC) is well established, but comprehensive characterization using routine sampling remains challenging. Autopsy-based research addresses this obstacle by enabling broad tissue collection within individual patients after treatment. In this issue of the JCI, Roudier et al. analyzed samples from a mPC research autopsy cohort, revealing extensive inter- and intratumor heterogeneity across patients and at the cellular level. The authors associated this variability with genomic, phenotypic, and clinical features and explored the importance of tumors expressing both androgen receptor and neuroendocrine markers. Their findings demonstrate heterogeneity across metastatic sites that may influence treatment response and clinical outcomes, informing future therapeutic strategies in mPC.
转移性前列腺癌（mPC）中的肿瘤异质性已得到充分证实，但使用常规采样进行全面表征仍具有挑战性。基于尸检的研究通过在治疗后对个体患者进行广泛的组织采集来解决这一障碍。在本期《临床研究杂志》（JCI）中，鲁迪耶等人分析了来自mPC研究尸检队列的样本，揭示了患者之间以及细胞水平上广泛的肿瘤间和肿瘤内异质性。作者将这种变异性与基因组、表型和临床特征相关联，并探讨了同时表达雄激素受体和神经内分泌标志物的肿瘤的重要性。他们的研究结果表明转移部位存在异质性，这可能会影响治疗反应和临床结果，为mPC未来的治疗策略提供了参考。
